INTRODUCTION:
Although prevention remains the cornerstone for the management of thalassemia, hematopoietic stem cell transplantation (HSCT) is the only curative approach. OBJECTIVE: Our goal was to assess our experience with HSCTs for the treatment of patients with thalassemia. METHODS: From 1994 From to 2006 HSCTs have been performed in 84 thalassemic children from Greece, 3 with sickle cell/thalassemia and 1 with sickle cell disease. According to Pesaro classification, of these 84 children, 20 were in class I, 35 were in class II, and 29 were in class III. Donors were 84 histocompatible siblings and 4 unrelated volunteers. The graft was of bone marrow in 85, cord blood in 3, bone marrow and cord blood in 4, and peripheral blood stem cells in 4. The conditioning regimen consisted of busulfan, cyclophosphamide, and antilymphocyte globulin. RESULTS: All except 1 patient received engraftments. Ten patients rejected the graft. Eight received another transplant from the same donor, 7 of which were successful. Four patients died; causes of death were graftversus-host disease (GVHD) (2), disseminated toxoplasmosis (1), and brain hemorrhage (1). At a median follow-up time of 6.5 years, 84 of 88 children survived, 81 were cured and free from transfusions, and 3 remained transfusion-dependent. Severe acute GVHD developed in 18 children, and chronic GVHD developed in 8 patients. The overall survival rate, event-free survival rate, rejection rate, and transplant-related mortality rate were 95%, 94%, 11%, and 5%, respectively. Event-free survival was 100% for class I, 95% for class II, and 87% for class III. Eleven children had mixed chimera (residual recipient hematopoiesis) with normal levels of hemoglobin. CONCLUSIONS: HSCT is a highly effective treatment for thalassemic patients who have a fully matched donor (related or unrelated). Younger age at transplant secures excellent results with reduced morbidity and mortality rates. 
TWO-DECADE EXPERIENCE AND LONG-TERM SURVIVAL IN PEDIATRIC NON-HODGKIN'S LYMPHOMA

INTRODUCTION:
Treatment results for pediatric nonHodgkin's lymphoma (NHL) continue to improve internationally. OBJECTIVE: Our goal was to evaluate patient characteristics in our series of patients with NHL and outcomes for the last 16 years (1990 -2006) . METHODS: Our patients included 52 newly diagnosed children (11 girls) with a median age of 8.40 years (range: 0.33-14.5 years). Histology results included Blymphocyte NHL, T-lymphocyte NHL, and Ki-1 in 35, 12, and 5 patients, respectively. In each 5-year period, 14 (3), 17 (3), and 21 (5) patients (girls) were diagnosed, respectively. Common presenting sites were the mediastinum (16), neck area (14), and abdomen (10). Disease was at stage I, II, III, and IV in 3, 14, 23, and 7 patients, respectively. Treatment varied over time. Berlin-Frankfurt-Munich (BFM) protocols had been applied since 1995 (BFM-NHL-90), and since 1997 the BFM-NHL-95 protocol had been applied. Irradiation was given to 5 patients (2 with B-NHL, 3 with T-NHL), and autologous stem cell transplantation was performed on 4 patients, all with B-NHL (1 with central nervous system disease, 1 with residual disease at the end of treatment, and 2 at relapse). RESULTS: At this writing, 41 patients are alive; 39, 2, and 1 are in first, second, and third remission, respectively. In total, 9 have succumbed (2 died soon after admission in other hospitals as a result of acute-phase complications), and 5 patients died during the first decade of our retrospective study (with T-histology and extensive disease). The event-free survival rate is 74.4% (39 of 52 patients), and the overall survival rate is 80.9% (41 of 52 patients), for a median follow-up time of 6.1 years (range: 0.01-14.7 years) for all patients. For the 39 patients treated with the BFM-95 protocol since 1997, event-free survival and overall survival rates are 79.4% and 88.2%, respectively, for a median follow-up time of 4.8 years. CONCLUSIONS: Overall and event-free survival rates and outcome of our patients with NHL treated during the last 16 years are standing high. There has been limited use of irradiation and stem cell transplantation. 
SERUM LEVELS OF MYCN AMPLIFICATION IN NEUROBLASTOMA WITH TUMOR-RELEASED DNA BY REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION Submitted by Tohru Sugimoto
OBJECTIVE:
We aimed to develop a diagnostic tool to predict MYCN status by using serum DNA, which, in patients with cancer, predominantly originates from tumor-released DNA. METHODS: Using DNA-based real-time quantitative polymerase chain reaction, we simultaneously quantified MYCN (2p24) and a reference gene, NAGK (2p12), and evaluated MYCN copy number as a MYCN/NAGK ratio in 87 patients with neuroblastoma whose MYCN status had been determined by Southern blotting. Of these patients, 17 had MYCN-amplified neuroblastoma, and 70 had nonamplified neuroblastoma.
RESULTS:
The serum MYCN/NAGK ratio in the MNA group (median: 199.32; range: 17.1-901.6 [99% confidence interval: 107.0 -528.7]) was significantly (P Ͻ .001) higher than that in the non-MNA group (median: 0.87; range: 0.25-4.6 [99% confidence interval: 0.82-1.26], Mann-Whitney U test). The sensitivity and specificity of the serum MYCN/NAGK ratio as a diagnostic test were both 100% when the serum MYCN/NAGK ratio cutoff was set at 10.0. Among 6 patients in the MNA group whose clinical courses were followed, the serum ratios decreased to within the normal range in the patients in remission (n ϭ 3), but they rose to high levels in the patients who had a relapse (n ϭ 2) or failed to achieve remission (n ϭ 1). The serum MYCN/NAGK ratio in the MNA group is likely to be the more sensitive tumor marker than conventional urinary vanillylmandelic and homovanillic acid markers and neuron-specific enolase markers to predict patients' clinical course. CONCLUSIONS: Measurement of the serum MYCN/ NAGK ratio seems to be a promising method for accurately assessing MYCN status in neuroblastoma. 
